FDA 2025 Breakthrough Drugs: Innovative Therapies for HIV, Cancer, Hemophilia and Rare Diseases Shaping the Future of Healthcare in Slovakia
Not all news is negative – alongside conflicts and uncertainty, there is a real hope that we will live longer and with a better quality of life. The year 2025 did not only bring stories about wars, political intrigues, the opening of the tunnel near Žilina or debates about the future of Greenland, but also major advances in new medicines and modern therapies that can improve patients’ lives in Slovakia as well.
FDA 2025: why new drugs matter for Slovakia
In 2025, the US Food and Drug Administration (FDA) approved dozens of new innovative drugs and again confirmed its position as the leading global regulator in pharmaceuticals. Many of these products have the potential to reach the European market and later Slovak patients through EMA decisions and national authorities.
From an indication perspective, the main areas were:
Oncology (new cancer therapies)
Haematology (bleeding and blood disorders)
Anti-infective agents (antibiotics, antivirals)
Treatments for rare diseases (orphan drugs)
A significant share of the pipeline consists of “first-in-class” medicines – products with completely new mechanisms of action or major innovation compared to current standards of care.
Lenacapavir: long-acting HIV prevention twice a year
Lenacapavir is the first long-acting injection for HIV pre-exposure prophylaxis (PrEP) approved by the FDA in 2025.
Key points:
Indication: prevention of HIV infection in people at high risk.
Dosing: subcutaneous injection once every six months.
Benefit: a major simplification of prevention compared with daily oral PrEP, with very high levels of protection in clinical trials.
For populations where daily adherence is a challenge, lenacapavir is considered a breakthrough. In the future, it may be relevant for Slovak HIV prevention strategies, especially in clearly defined high-risk groups.
Suzetrigine (Journavx): acute pain without opioids
Suzetrigine (Journavx) is a next-generation non-opioid analgesic highlighted among the most interesting FDA approvals of 2025.
Key points:
Indication: treatment of acute moderate to severe pain.
Mechanism: different from classical opioids, with no typical opioid-related dependence and serious side effects.
Although final efficacy was slightly below the most optimistic expectations, experts see suzetrigine as an important step to diversify pain management. In systems aiming to reduce opioid use, it offers a potential alternative or add-on to existing analgesic therapies.
Gepotidacin: a new oral antibiotic for resistant gonorrhoea
After almost 30 years, a new oral antibiotic for gonorrhoea has emerged – gepotidacin.
Key points:
Disease: gonorrhoea, a sexually transmitted infection with rising resistance to existing antibiotics.
Mechanism: inhibition of bacterial DNA replication via DNA gyrase, but in a different way than classical fluoroquinolones.
Because of its distinct mechanism, gepotidacin remains active against strains resistant to older antibiotics. Even though future resistance is possible with misuse, its arrival significantly strengthens our options in treating gonorrhoea and potentially other infections.
New oncology therapies: ovarian cancer and diffuse gliomas
Avutometinib + defactinib: targeted therapy for ovarian cancer
A key step forward in ovarian cancer treatment is the combination of two small molecules – avutometinib and defactinib.
Key points:
Both are kinaseinhibitors, targeting enzymes central to protein phosphorylation and cell signalling.
The combination represents a modern targeted therapy approach in oncology.
The regimen received accelerated FDA approval based on data from a relatively small study, so its long-term role will depend on confirmatory phase III trials. Early data also suggest potential activity in pancreatic cancer, opening additional clinical opportunities.
Dordaviprone: a new option for diffuse midline glioma
Dordaviprone is another important oncology innovation, developed for diffuse midline glioma with H3 K27M mutation in patients over one year of age.
Key points:
This is a highly aggressive brain tumour with extremely poor prognosis.
Until recently, radiotherapy was almost the only systemic treatment option.
Dordaviprone obtained accelerated approval after several clinical studies demonstrated clinically relevant responses in a subset of patients. Although overall response rates are modest, any effective systemic option in this setting represents a major step forward.
Fitusiran (Qfitlia): siRNA therapy for haemophilia A and B
Fitusiran (Qfitlia, Sanofi) is an innovative siRNA therapy designed to reduce bleeding in patients with haemophilia A or B, both with and without inhibitors.
Key points:
Mechanism: targeted reduction of antithrombin, a natural anticoagulant, which increases thrombin generation and improves haemostasis.
Dosing: low-frequency subcutaneous injections (several times per year).
Efficacy: clinical trials show substantial reductions in annual bleeding rates, with some patients experiencing no bleeding episodes.
Fitusiran is associated with risks such as thrombosis and other adverse events, and therefore carries a boxed safety warning. It requires careful patient selection and close monitoring. Despite this, it is widely viewed as a paradigm-shifting therapy – moving haemophilia treatment from clotting factor replacement towards modulation of the patient’s own coagulation system.
Papzimeos: gene therapy for respiratory papillomatosis
Papzimeos is a novel gene therapy for patients with recurrent respiratory papillomatosis, a disease in which HPV-induced papillomas form in the airways.
Key points:
Previous standard of care: repeated surgery to maintain airway patency.
New approach: a vector based on gorilla adenovirus delivers a genetic construct that activates the immune system against HPV-infected cells.
In clinical studies, a small number of injections led to complete disappearance of papillomas in a significant proportion of patients and markedly reduced the need for further surgeries in most others. The gorilla adenovirus vector has low immunogenicity and high capacity for genetic cargo, paving the way for future complex gene therapies.
Key therapeutic trends from FDA approvals 2025
Across these examples, several clear trends emerge in modern pharmacotherapy:
Shift towards long-acting injectable formulations (e.g. lenacapavir)
Rapid expansion of RNA-based therapies (siRNA and other RNA modalities, such as fitusiran)
Development of gene therapies with new, higher-capacity viral vectors (e.g. Papzimeos)
Systematic effort to reduce dependency on opioids via new analgesics (suzetrigine)
Strong focus on rare and hard-to-treat diseases (diffuse midline glioma, specific cancers, haemophilia, respiratory papillomatosis)
These innovations not only transform clinical practice but also significantly impact healthcare budgeting, distribution logistics and how health systems evaluate value and cost-effectiveness.
How this helps Investpharm clients and partners
For Investpharm, this landscape of FDA 2025 approvals is not just global news – it is a strategic roadmap.
It enables early identification of promising molecules that may reach the European and Slovak markets in the coming years.
It helps our team and partners prepare in advance for regulatory submissions, distribution models, reimbursement negotiations and clinical integration.
It demonstrates to existing and potential clients that Investpharm actively monitors global pharmaceutical trends, understands emerging therapies and can support the introduction of innovative medicines into local practice.
For manufacturers, healthcare providers, pharmacies and payers, having a partner who truly understands where innovative pharmacotherapy is heading – from HIV prevention and oncology to haemophilia and gene therapies for rare diseases – is crucial. Investpharm aims to be exactly this kind of partner: a reliable link between manufacturers, regulators and patients, helping ensure that modern medicines reach the people who need them most in Slovakia and across the region.
Sources
[1] US Food and Drug Administration – Novel Drug Approvals for 2025 (oficiálne prehľady nových schválení).
[2] Prehľady odborných portálov a analytické články o najvýznamnejších schváleniach FDA v roku 2025 (najmä v oblastiach HIV, onkológie, hemofílie a antibiotík).
[3] Odborné texty a komentáre k inovatívnym terapiám roku 2025 (lenakapavir, suzetrigine, gepotidacín, kombinácia avutometinib + defactinib, dordaviprone, fitusiran, Papzimeos).
Planning to register an innovative drug in 2026? → [Registration Services in EU and CIS]